Eterna Therapeutics Inc (ERNA NASDAQ) stock market data APIs
$2.1738
-0.09(-4.1%)
as of October 15, 2026
Try our APIs with
free plan!
Eterna Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Prev. Close
2.1738
Open
2.0828
High
2.2399
Low
2.0535
52 wk Range
2.0127-48
Market Cap
3 542 K
Shares Outstanding
1 632 K
Revenue
1 000
EPS
-3.4
Beta
2.646
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Eterna Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eterna Therapeutics Inc data using free add-ons & libraries
Get Eterna Therapeutics Inc Fundamental Data
Eterna Therapeutics Inc Fundamental data includes:
- Net Revenue: 1 000
- EBITDA: -11 691 000
- Earnings Per Share: -12
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -3.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eterna Therapeutics Inc News
New
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Ernexa Therapeutics Inc. Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and ...
Three Biotechs Deliver Catalysts to Watch
DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ: NTHI), Ernexa Therapeutics(NASDAQ: ERNA), and VivoSim Labs(NASDAQ: VIVS) hi...
PayPal jumps on reported takeover bid, Aehr Test soars
Investing.com -- U.S. stock index futures edged higher on Wednesday after softer inflation data and a strong start to the corporate earnings season boosted investor sentiment, with markets weighing wh...
Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS?
(RTTNews) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which has revised i...
Get Eterna Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.